^
Association details:
| Biomarker: | PTEN mutation |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Talzenna (talazoparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes
Published date:
10/17/2022
Excerpt:
All enrolled patients were treated with talazoparib monotherapy...Five patients with SD as their best response remained on therapy for more than 30 weeks, including a patient with testicular cancer with a gCHEK2 mutation, a patient with colon cancer with a gATM mutation and three patients with breast cancer with sPTEN, gPALB2 or sATR mutations. Of the four patients who achieved a PR as their best response, three remained on therapy for >35 weeks.
DOI:
https://doi.org/10.1038/s43018-022-00439-1
Trial ID:
